Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 18/20 | 1.00 |
| ▸ | CSNK1D | P48730 | 5/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 3/20 | 1.00 |
| ▸ | MAPK12 | P53778 | 3/20 | 1.00 |
| ▸ | MAPK11 | Q15759 | 3/20 | 1.00 |
| ▸ | CSNK1E | P49674 | 2/20 | 1.00 |
| ▸ | EGFR | P00533 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.80 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.80 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.80 |
| ▸ | MINK1 | Q8N4C8 | 3/20 | 0.80 |
| ▸ | MAP4K5 | Q9Y4K4 | 3/20 | 0.80 |
| ▸ | LCK | P06239 | 2/20 | 0.80 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.80 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.80 |
| ▸ | PRKACA | P17612 | 2/20 | 0.80 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.80 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.80 |
| ▸ | PRKCG | P05129 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20550488 | 1.00 | MAPK14 (1.00) | MAPK14CSNK1DMAPK13MAPK12MAPK11 | |
| SCHEMBL12280165 | 1.00 | MAPK14 (1.00) | MAPK14CSNK1DMAPK13MAPK12MAPK11 | |
| Hydrochloric Acid SCHEMBL18921552 | 0.99 | MAPK14 (0.98) | MAPK14CSNK1DMAPK13MAPK12MAPK11 | |
| Hydrochloric Acid SCHEMBL20550765 | 0.99 | MAPK14 (0.98) | MAPK14CSNK1DMAPK13MAPK12MAPK11 | |
| SCHEMBL20550893 | 0.99 | MAPK14 (0.98) | MAPK14CSNK1DMAPK13MAPK12MAPK11 | |
| SCHEMBL29842083 | 0.99 | MAPK14 (0.98) | MAPK14CSNK1DMAPK13MAPK12MAPK11 | |
| SCHEMBL20550876 | 0.97 | MAPK14 (0.93) | MAPK14CSNK1DMAPK13MAPK12MAPK11 | |
| SCHEMBL20550753 | 0.95 | MAPK14 (0.91) | MAPK14CSNK1DMAPK13MAPK12MAPK11 | |
| SCHEMBL7802983 | 0.91 | MAPK14 (0.83) | MAPK14CSNK1DMAPK13MAPK12MAPK11 | |
| SCHEMBL4912960 | 0.90 | MAPK14 (1.00) | MAPK14CSNK1DMAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240398758-A1 | METHODS FOR IDENTIFYING AND USING INHIBITORS OF CASEIN KINASE 1 EPSILON ISOFORM FOR INHIBITING THE GROWTH AND/OR PROLIFERATION OF MYC-DRIVEN TUMOR CELLS | FRED HUTCHINSON CANCER CENTER | 2024-12-05 | — | — | US | claimed |
| CN-113301900-B | Use of casein kinase 1 inhibitors for the treatment of vascular diseases | 夸纳特制药股份公司 | 2024-11-29 | — | — | CN | claimed |
| US-20230126310-A1 | COMPOSITIONS FOR CORONAVIRUS INFECTION TREATMENT AND/OR PREVENTION | FRAUNHOFER GES FORSCHUNG (DE) | 2023-04-27 | — | — | US | claimed |
| EP-4126234-A1 | COMPOSITIONS FOR CORONAVIRUS INFECTION TREATMENT AND/OR PREVENTION | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2023-02-08 | — | — | EP | claimed |
| CN-115474430-A | Composition for treatment and/or prevention of coronavirus infection | 弗劳恩霍夫应用研究促进协会 | 2022-12-13 | — | — | CN | claimed |
| WO-2022234494-A2 | METHODS AND COMPOSITIONS FOR INTERFERING WITH FAN1 | THE HOSPITAL FOR SICK CHILDREN (CA) | 2022-11-10 | — | — | WO | claimed |
| US-20220226318-A1 | Compounds for treatment of diseases related to DUX4 expression | Facio Intellectual Property B.V. (NL) | 2022-07-21 | — | — | US | claimed |
| US-20220047598-A1 | Use of Casein Kinase 1 Inhibitors For Treating Vascular Diseases | QANATPHARMA AG (CH) | 2022-02-17 | — | — | US | claimed |
| US-20260098245-A1 | Differentiation Method | KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN (NL) | 2026-04-09 | — | — | US | disclosed |
| US-12590297-B2 | Differentiation method | KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN (NL) | 2026-03-31 | — | — | US | disclosed |
| EP-3877382-B1 | NOVEL COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES | TIANLI BIOTECH PTY LTD (AU) | 2026-03-18 | — | — | EP | disclosed |
| US-12558358-B2 | N-(furan-2-ylmethyl)-7H-purin-6-amine for treatment of circadian rhythm diseases, disorders and dysfunctions | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2026-02-24 | — | — | US | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2025245059-A1 | COMPOSITIONS COMPRISING GSK-3 AND/OR BETA-CATENIN INHIBITORS AND/OR DEGRADERS AND METHODS OF USE THEREOF | YALE UNIVERSITY (US) | 2025-11-27 | — | — | WO | disclosed |
| EP-3982955-A1 | CASEIN KINASE 1 INHIBITORS FOR USE IN THE TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION SUCH AS MUSCULAR DYSTROPHY AND CANCER | Facio Intellectual Property B.V. (NL) | 2022-04-20 | — | — | EP | disclosed |
| WO-2022058920-A1 | CASEIN KINASE 1 DELTA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-03-24 | — | — | WO | disclosed |
| EP-3774795-B1 | 4-(1H- IMIDAZOL- 5- YL) -1H-PYRROLO [2, 3-B] PYRIDINES FOR USE IN THE TREATMENT OF LEUKAEMIAS, LYMPHOMAS AND SOLID TUMORS | UNIV MASARYKOVA (CZ) | 2022-03-16 | — | — | EP | disclosed |
| US-20220073998-A1 | Methods and Compositions For Identifying And Treating Patients With Small Cell Lung Cancer | UNIVERSITY OF UTAH | 2022-03-10 | — | — | US | disclosed |
| EP-3964512-A1 | CASEIN KINASE 1epsilon INHIBITOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Hangzhou Healzen Therapeutics Co., Ltd. (CN) | 2022-03-09 | — | — | EP | disclosed |
| US-20220047598-A1 | Use of Casein Kinase 1 Inhibitors For Treating Vascular Diseases | QANATPHARMA AG (CH) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260098245-A1 | Differentiation Method | GAPDH, ALPG, PYGL | MAPK14 1572/4885CSNK1D 52/4885MAPK13 1643/4885 |
| US-20240398758-A1 | METHODS FOR IDENTIFYING AND USING INHIBITORS OF CASEIN KINASE 1 EPSILON ISOFORM FOR INHIBITING THE GROWTH AND/OR PROLIFERATION OF MYC-DRIVEN TUMOR CELLS | CSNK1E, CSNK1A1, CSNK1G1 | MAPK14 383/4885CSNK1D 8/4885MAPK13 441/4885 |
| US-20220226318-A1 | Compounds for treatment of diseases related to DUX4 expression | ZFX, MTPN, UTRN | MAPK14 4441/4885CSNK1D 2691/4885MAPK13 3650/4885 |
| US-12558358-B2 | N-(furan-2-ylmethyl)-7H-purin-6-amine for treatment of circadian rhythm diseases, disorders and dysfunctions | PER2, CRY1, TPMT | MAPK14 2292/4885CSNK1D 470/4885MAPK13 2924/4885 |
| US-12590297-B2 | Differentiation method | WNT3A, SFRP1, WNT1 | MAPK14 1553/4885CSNK1D 47/4885MAPK13 1921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.